Advertisement

Related Videos

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Jul
09
Today In Oncology
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo